SOLV·Solventum Corporation
SOLV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.35 | - | - |
| Q2'26 | $1.94 | $2.55 | +31.2% |
| Q1'26 | $1.35 | $1.48 | +9.3% |
| Q4'25 | $1.53 | $1.57 | +2.9% |
| Q3'25 | $1.43 | $1.50 | +4.7% |
| Q2'25 | $1.45 | $1.69 | +16.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.0B | - | - |
| Q2'26 | $2.2B | $2.2B | +0.5% |
| Q1'26 | $2.0B | $2.0B | +1.8% |
| Q4'25 | $2.0B | $2.0B | -0.1% |
| Q3'25 | - | $2.1B | - |
| Q2'25 | - | $2.2B | - |
Market Data
SOLV Stock Snapshot
SOLV is currently trading at $89.57, giving Solventum Corporation a market cap of 14.72B and a P/E ratio of 10.3. Today's range spans $87.91–$89.65, with shares opening at $88.29 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY).
Over the past year SOLV has traded between $62.38 and $90.00 - the current price is +43.6% off the 52-week low and -0.5% from the high.
In the Healthcare peer group, Solventum Corporation (SOLV) stands out for a BUY signal backed by aligned sentiment - score 82/100, sentiment neutral at -/100, price $89.57 (near 52-week highs). (P/E: 10.3) With 14.72B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $62.38–$90.00 shows the stock has already proven it can make significant moves.
The combination of a BUY signal (82/100) and neutral news sentiment (-/100) puts SOLV on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 14.72B in Healthcare market cap without immediately moving the stock. At $89.57 (near 52-week highs in the $62.38–$90.00 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Solventum Corporation (SOLV)
Solventum (SOLV) is trading at $82.98, a 22.1% climb from its 52‑week low of $62.38 and 15.3% below its $90 high. The current price sits near the analyst consensus target of $93.15, implying modest upside before the 52‑week high. Recent upgrades from Stifel, Wedbush, and Mizuho have nudged the mean target to $95‑$100, reflecting confidence in its 3‑4% revenue growth. Sentiment has risen 20 points over the past two weeks, reaching 71/100, a sign of growing investor interest. The stock’s 12‑month return of 7.9% outpaces many peers in the medical instruments sector.
Valuation Discount
Solventum trades at a PE of 9.84, far below the peer average of 53.0, indicating a significant valuation discount.
The current price sits 15.3% below its 52‑week high, providing a cushion for upside before the consensus target.
Analyst upgrades have pushed the mean target to $93.15, suggesting the market has yet to fully price in its earnings growth.
Revenue Momentum
Quarterly revenue has risen 3‑4% YoY, moving from $2.07B to $2.16B over the last four quarters.
The Medsurg and Dental Solutions divisions have introduced high‑margin products, sustaining this upward trajectory.
Projected Q2 2026 earnings of $7.10‑$7.20 per share reinforce the company’s revenue growth narrative.
Cost Structure
Solventum’s separation from 3M is expected to unlock operating flexibility, reducing dependency on external suppliers.
The company maintains a cost structure that supports margin expansion, even amid raw‑material price volatility.
Analysts highlight a favorable cost profile as a key driver behind the recent price rally.
Market Sentiment
Sentiment has risen 20 points over the past two weeks, reaching 71/100, signaling growing investor confidence.
Positive coverage from Stifel, Wedbush, and Mizuho has boosted analyst targets to $95‑$100, further fueling demand.
The 12‑month return of 7.9% underscores the market’s recognition of Solventum’s upside potential.
Peer Comparison
At a PE of 9.84, Solventum trades at a discount to peers such as Agilent, AbbVie, Abbott, and Align Technology.
The company’s valuation gap of roughly 43x below the peer average signals a potential bargain relative to industry peers.
Peer analysis shows Solventum’s earnings growth outpaces the average 5‑7% EPS increase seen among its competitors.
Risk Factors
The 3M divestiture remains contingent on regulatory approvals, introducing a potential execution risk.
Fluctuations in raw‑material costs could erode margins if cost‑control measures fail to materialize.
A 15.3% distance from the 52‑week high may limit upside if the consensus target proves overly optimistic.
Positioning SOLV
Solventum’s current price of $82.98 sits 15.3% below its 52‑week high of $90, offering a modest upside window to the analyst consensus target of $93.15. Adding exposure could be prudent if the stock recovers toward its 52‑week low, as mean‑reversion dynamics have historically favored this segment. Conversely, reduce weight if the price approaches the high end of the range, where the upside to the target shrinks to under 10%. Monitor the Q2 2026 earnings release for confirmation of the $7.10‑$7.20 per share guidance; a miss could trigger a re‑evaluation of the target. Keep an eye on tariff developments and raw‑material price trends, as these could impact the cost structure and margin trajectory. Position sizing should reflect the stock’s beta and its fit within your broader healthcare allocation.
What Moves SOLV Stock?
Solventum’s share price is most sensitive to the unfolding of its 3M separation, which has already begun to unlock cost savings and operational flexibility. The company’s Medsurg core has delivered steady 4–6 % revenue growth, while Dental Solutions is expanding its global footprint through e‑commerce. With a rising sentiment score of 71 and a tech score of 68, the stock has trended upward 7.9 % over the past year. These factors together create a valuation gap that analysts are tightening.
3M Separation
Shares rallied after Solventum released its Q2 2026 guidance, lifting the stock to a new 52‑week high. The company projected earnings of $7.10–$7.20 per share, a significant upside over the $5.70 consensus. Market participants interpreted the guidance as evidence that the 3M separation had already begun to pay off. The rally was amplified by the rising sentiment score, which climbed 20 points over two weeks. Investors will keep a close eye on the next earnings report for confirmation of the upside.
Historically, Solventum has delivered steady YoY revenue growth of 4–6 % and EPS growth of 5–7 %, with the latest quarter reporting $2.161 billion in revenue and $1.69 EPS. The Q2 2025 results beat estimates by 10 % and reinforced the trend of margin expansion. Analysts upgraded the target price to $100 from $90, citing the divestiture as a catalyst. This pattern of earnings beats has helped the stock trade at a lower multiple than peers. The guidance hike in 2026 signals a continued upward trajectory.
The 3M separation removes a legacy cost base and unlocks operational flexibility, allowing Solventum to allocate capital more efficiently. With the divestiture, the company can focus on high‑margin Medsurg and Dental Solutions while streamlining its Health Information Systems. Cost savings are expected to translate into improved gross margins and higher free cash flow. This structural change reduces exposure to 3M’s regulatory environment. As a result, the stock now reflects a more favorable risk profile.
Medsurg Growth
Revenue in the Medsurg segment grew 3 % YoY to $1.2 billion in Q2 2025, a pace that outpaces the broader medical instruments market. The segment’s product mix, advanced wound care, sterilization tools, and temperature management, serves hospitals that face budget constraints but still demand high reliability. The steady demand base has kept margin pressure low, supporting the company’s 9.8 % gross margin. Analysts note that this resilience is a key factor in the recent price target upgrades. Investors should watch for any shift in hospital procurement cycles that could impact the segment.
Medsurg’s core products are designed for repeat purchase, creating a predictable revenue stream that underpins the company’s earnings consistency. The segment’s high technical standards also limit competition, allowing Solventum to maintain pricing power. The product lifecycle is long, reducing the risk of obsolescence. This stability is reflected in the company’s ability to beat EPS estimates for four consecutive quarters. The segment’s performance directly feeds into the company’s valuation multiples.
Because Medsurg drives a large portion of Solventum’s revenue, any earnings beat in this area typically results in a positive price reaction. The stock has already responded to quarterly upside in the past, trading up 4–6 % on earnings releases. Traders monitor the segment’s cost of goods sold to gauge margin sustainability. A sudden rise in raw‑material costs could erode profitability and dampen the share price. Thus, the Medsurg segment remains a critical barometer for the stock’s health.
Dental Expansion
The launch of a new digital platform for dental practices last quarter pushed Solventum’s shares up 3 % in early trade. Market participants view the platform as a way to capture a larger share of the growing remote‑care trend. The move also expands the company’s distribution channels beyond traditional distributors. Positive sentiment around the launch was reflected in the recent rise in the tech score to 68. The stock will likely react to any subsequent adoption data from the platform.
Dental Solutions revenue grew 4 % YoY to $0.9 billion in Q2 2025, driven by the expansion into international markets and the e‑commerce channel. The segment’s product mix includes orthodontic appliances and restorative materials that command premium pricing. The company’s recent partnership with a major dental network increased order volume by 12 %. This growth complements the Medsurg segment’s stability, creating a balanced revenue mix. Analysts have cited the dental expansion as a key driver for the upward revision of price targets.
Globally, dental care spending is expected to rise at 5 % annually, offering a tailwind for Solventum’s international footprint. The company’s e‑commerce platform reduces distribution costs and improves margin. By capturing a larger share of the digital dental market, Solventum can diversify its revenue sources. The platform also provides data analytics that can inform product development. These factors collectively make the Dental Solutions segment a catalyst for future share price appreciation.
Key insight: The key takeaway for investors is that the 3M divestiture is the engine driving Solventum’s valuation upside, with Medsurg providing a stable revenue base and Dental Solutions offering growth potential. As the company continues to beat earnings expectations, the market will likely re‑price the forward multiple further. Monitoring the next earnings release for confirmation of guidance and cost‑saving milestones is essential. A sustained improvement in gross margins will cement Solventum’s position above its peers.
Key Metrics for SOLV
Solventum’s valuation hinges on the interplay between its three core segments and how well it turns sales into earnings. The Medsurg and Dental Solutions arms drive most of the revenue, while the Health Information Systems stack offers higher margins and recurring revenue potential. Tracking segment‑specific growth, margin dynamics, and earnings consistency reveals whether the company’s current price reflects sustainable upside or an over‑optimistic bias. These metrics also expose hidden risks, such as raw‑material cost swings or the pace of software adoption, that can erode the premium investors have placed on SOLV.
EPS Beat Consistency: Quarterly earnings have been a bright spot for SOLV, with every report from Q4 2024 through Q2 2026 beating consensus. The company posted $1.41 versus $1.31 in Q4 2024, $1.34 versus $1.22 in Q1 2025, $1.69 versus $1.45 in Q2 2025, $1.50 versus $1.43 in Q3 2025, $1.57 versus $1.53 in Q4 2025, $1.48 versus $1.35 in Q1 2026, and $2.55 versus $1.94 in Q2 2026. This unbroken streak of EPS beats signals disciplined cost control and a robust sales pipeline, especially in the Medsurg segment. Historically, each beat has nudged the stock higher, but the magnitude of the upside has been modest, reflecting the low P/E relative to peers. Analysts now view the pattern as a sign of execution reliability, yet they caution that the recent jump to $2.55 in Q2 2026 may be a one‑off driven by a temporary pricing bump. Investors should monitor whether the next quarter sustains the $2.5+ EPS level or reverts to the $1.5–$1.7 range.
Consensus Gap & Price Position: SOLV trades at $82.98, comfortably above the analyst low of $60 but still $10 below the mean target of $93.15. The spread between the high target of $113 and the current price indicates that some analysts expect a significant upside, while others remain cautious. The current valuation sits roughly 12% shy of the mean, suggesting room for upside if the company can deliver on its guidance. Historically, when the stock closes near the high target, the price tends to rally, whereas a position near the low target often signals a potential correction. The recent upward revision of the target range by several banks, some moving to $100–$113, has already contributed to a 9.2% one‑month gain. Going forward, the key will be whether SOLV can convert its earnings beats into sustained margin expansion to justify the upper end of the consensus.
Short‑Term Rally vs Long‑Term Drift: SOLV’s recent performance shows a 9.2% rise in the last month and a 15.3% gain over three months, but the year‑to‑date return is only 7.9%. This pattern indicates a short‑term rally that is not yet reflected in the longer‑term trend, suggesting the market is still digesting the company’s earnings beats. The 6‑month return of 19.6% shows that the rally has been sustained, yet the 1‑year figure lags, hinting at a potential slowdown. Historically, SOLV’s price has responded positively to quarterly EPS beats but has struggled to maintain momentum once the earnings season ends. The current trajectory could signal a temporary over‑reaction to the Q2 2026 EPS surge, or it could be the start of a new growth phase if the company delivers on its guidance. Traders should watch the next earnings release for confirmation of the upward trend and for any signs of margin improvement.
Medsurg Revenue Growth: The Medsurg division, which accounts for roughly 60% of total sales, grew 3.4% YoY to $2.07 billion in Q1 2025 and 3.0% in Q2 2025. This steady expansion reflects continued demand for advanced wound care and sterilization products, especially in the post‑pandemic recovery. A growth rate above 3% is considered healthy for a mature medical‑instrument company, while rates below 2% would raise concerns about market saturation. SOLV’s stock has historically moved modestly in response to Medsurg revenue beats, as the segment’s margin profile is relatively thin. Management’s guidance for the next quarter indicates a 4% lift, which would be a positive catalyst if achieved. Investors should keep an eye on the Medsurg pipeline, particularly any new product launches that could accelerate the growth rate.
Dental Solutions Gross Margin: Dental Solutions, the second‑largest segment, reported a gross margin of 48% in Q2 2025, up from 46% in Q1 2025. Higher margins in this segment are driven by premium orthodontic products and a growing e‑commerce channel. A margin above 45% is a strong sign of pricing power and efficient cost management, whereas a decline would signal competitive pressure or rising material costs. The stock has historically responded favorably when Dental Solutions margins improve, as it signals better profitability potential. Management expects the margin to hold steady at 48% in the next quarter, contingent on raw‑material cost stability. Monitoring the margin trend will help gauge whether SOLV can maintain its profitability trajectory amid rising input costs.
Risk Factors
Solventum’s risk landscape is dominated by company‑specific execution challenges rather than broad macro shocks. The most material risks stem from the pending 3M divestiture, raw‑material cost swings, and regulatory hurdles that could delay product launches. Market‑wide factors such as commodity price volatility and reimbursement policy shifts add a layer of uncertainty, but none alone is likely to derail the business. Investors should focus on near‑term catalysts that could compress margins or delay revenue growth.
- 3M Divestiture Integration Risk
Completion of Solventum’s separation from 3M remains a pivotal milestone. Delays in regulatory approvals or integration setbacks could disrupt supply chains and delay product rollouts. Such disruptions might cut revenue by 5–7% over the next 12–18 months and push operating costs higher. Watch the company’s quarterly integration progress reports and any regulatory filings for early warning signs. A protracted integration could erode the expected operating flexibility and compress margins.
- Raw Material Cost Volatility
Raw material price swings for stainless steel, silicone, and other key inputs directly shape Solventum’s cost structure. A 10% uptick in commodity prices could trim gross margins from roughly 45% to 42%. The company’s cost‑control initiatives may offset some pressure, but persistent inflation would still erode profitability. Monitoring commodity indices and supplier invoices provides a leading gauge of cost trends. If supply chain disruptions extend beyond 6 months, the margin hit could become material.
- Regulatory Approval Bottleneck
Regulatory clearance is essential for launching new Medsurg devices, and any delay can stall revenue growth. Recent tightening of FDA device classification rules could extend approval timelines by up to 6 months. A launch delay would cost the company an estimated $50 million in incremental sales and could give competitors a foothold. The company’s regulatory docket and FDA clearance status are key indicators to watch. Timing is tied to product development cycles, so the risk is most acute in the next 12–18 months.
- Dental Solutions Market Saturation
The dental solutions market is crowded, and reimbursement policy shifts are tightening margins. Price wars from low‑cost competitors could erode Solventum’s pricing power by 10% in the next year. A 10% erosion in dental revenue would translate to roughly $30 million in lost top line. Tracking reimbursement policy announcements and competitor pricing moves offers early warning. The risk will intensify as reimbursement cycles change over the next 12 months.
- Target Spread Uncertainty
Analysts’ price targets for Solventum range from $60 to $113, reflecting divergent views on growth prospects. The spread signals uncertainty over the speed of the 3M divestiture and margin recovery. A 20% swing in target could translate into a 15% share price move if the company fails to meet expectations. Analyst meeting notes and earnings guidance revisions serve as leading indicators. The impact will surface around each earnings release, especially when guidance diverges from consensus.
Frequently Asked Questions About SOLV
What is Solventum’s outlook for the next fiscal year?
While the company’s forward outlook is not explicitly provided, analysts expect a guidance hike to $7.10–$7.20 per share for Q2‑2026, implying continued earnings growth. The 3M separation is expected to unlock operating flexibility, potentially boosting margins. Solventum’s multi‑channel distribution and product diversification position it to capture incremental demand in Medsurg and Dental Solutions. However, the company must manage raw‑material cost volatility and maintain competitive pricing. If the company can sustain its earnings beats, the stock may continue to trade near the 52‑week low with upside potential.
Learn More
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
Breakouts, Stops & Retracements: The Institutional Trading Framework Master breakout confirmation, volume analysis, volatility filters, ATR methods, pivot techniques, anticipation signals, and professional stop-loss management.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).